Antigen-specific augmentation of delayed-type hypersensitivity by immune serum factor in mice

Augmentation of anti-tumor cytostatic activity

Seiji Nakamura, Kunisuke Himeno, Akira Yamada, Masamitsu Mitani, Kikuo Nomoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A humoral factor capable of augmenting delayed-type hypersensitivity antigen specificity (DAF) is present in the serum of mice sensitized with heterologous erythrocytes to induce a delayed footpad reaction (DFR). In the present study, a similar factor was identified when xenogeneic tumor cells were used as antigens. This factor also could augment the in vitro anti-tumor cytostatic activity against homologous tumor cells, which correlated with in vivo DFR to the same tumor cells. The cytostatic activity augmented by the transfer of this factor had the following characteristics: (i) The activity appeared in the whole peritoneal exudate cells (PEC) from serum recipients at 4 days after the antigenic challenge. (ii) Such an activity was revealed in the collaboration of plastic dish-nonadherent and -adherent PEC as the primary and final effectors, respectively. (iii) The appearance of primary effector cells for such an activity was also accelerated in spleen and lymph node cells. (iv) However, a sufficient number of macrophages were always required as the final effectors in their functional expression. (v) These primary effectors were sensitized T lymphocytes which produced lymphokine(s) such as macrophage-activating factors) and which contributed to this augmented cytostatic activity through the activation of macrophages. Thus, this immune serum factor seems to exert functional expression by accelerating the generation of lymphokine-producing delayed-type T lymphocytes, which is also responsible for cytostatic anti-tumor immunity.

Original languageEnglish
Pages (from-to)311-325
Number of pages15
JournalCellular Immunology
Volume103
Issue number2
DOIs
Publication statusPublished - Jan 1 1986

Fingerprint

Delayed Hypersensitivity
Immunologic Factors
Cytostatic Agents
Immune Sera
Antigens
Neoplasms
Lymphokines
Exudates and Transudates
Macrophage-Activating Factors
T-Lymphocytes
Transfer Factor
Macrophage Activation
Serum
Plastics
Immunity
Spleen
Erythrocytes
Lymph Nodes
Macrophages

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

Antigen-specific augmentation of delayed-type hypersensitivity by immune serum factor in mice : Augmentation of anti-tumor cytostatic activity. / Nakamura, Seiji; Himeno, Kunisuke; Yamada, Akira; Mitani, Masamitsu; Nomoto, Kikuo.

In: Cellular Immunology, Vol. 103, No. 2, 01.01.1986, p. 311-325.

Research output: Contribution to journalArticle

Nakamura, Seiji ; Himeno, Kunisuke ; Yamada, Akira ; Mitani, Masamitsu ; Nomoto, Kikuo. / Antigen-specific augmentation of delayed-type hypersensitivity by immune serum factor in mice : Augmentation of anti-tumor cytostatic activity. In: Cellular Immunology. 1986 ; Vol. 103, No. 2. pp. 311-325.
@article{6493fbb498e24c39bd65e808ceecb1cb,
title = "Antigen-specific augmentation of delayed-type hypersensitivity by immune serum factor in mice: Augmentation of anti-tumor cytostatic activity",
abstract = "A humoral factor capable of augmenting delayed-type hypersensitivity antigen specificity (DAF) is present in the serum of mice sensitized with heterologous erythrocytes to induce a delayed footpad reaction (DFR). In the present study, a similar factor was identified when xenogeneic tumor cells were used as antigens. This factor also could augment the in vitro anti-tumor cytostatic activity against homologous tumor cells, which correlated with in vivo DFR to the same tumor cells. The cytostatic activity augmented by the transfer of this factor had the following characteristics: (i) The activity appeared in the whole peritoneal exudate cells (PEC) from serum recipients at 4 days after the antigenic challenge. (ii) Such an activity was revealed in the collaboration of plastic dish-nonadherent and -adherent PEC as the primary and final effectors, respectively. (iii) The appearance of primary effector cells for such an activity was also accelerated in spleen and lymph node cells. (iv) However, a sufficient number of macrophages were always required as the final effectors in their functional expression. (v) These primary effectors were sensitized T lymphocytes which produced lymphokine(s) such as macrophage-activating factors) and which contributed to this augmented cytostatic activity through the activation of macrophages. Thus, this immune serum factor seems to exert functional expression by accelerating the generation of lymphokine-producing delayed-type T lymphocytes, which is also responsible for cytostatic anti-tumor immunity.",
author = "Seiji Nakamura and Kunisuke Himeno and Akira Yamada and Masamitsu Mitani and Kikuo Nomoto",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/0008-8749(86)90092-4",
language = "English",
volume = "103",
pages = "311--325",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Antigen-specific augmentation of delayed-type hypersensitivity by immune serum factor in mice

T2 - Augmentation of anti-tumor cytostatic activity

AU - Nakamura, Seiji

AU - Himeno, Kunisuke

AU - Yamada, Akira

AU - Mitani, Masamitsu

AU - Nomoto, Kikuo

PY - 1986/1/1

Y1 - 1986/1/1

N2 - A humoral factor capable of augmenting delayed-type hypersensitivity antigen specificity (DAF) is present in the serum of mice sensitized with heterologous erythrocytes to induce a delayed footpad reaction (DFR). In the present study, a similar factor was identified when xenogeneic tumor cells were used as antigens. This factor also could augment the in vitro anti-tumor cytostatic activity against homologous tumor cells, which correlated with in vivo DFR to the same tumor cells. The cytostatic activity augmented by the transfer of this factor had the following characteristics: (i) The activity appeared in the whole peritoneal exudate cells (PEC) from serum recipients at 4 days after the antigenic challenge. (ii) Such an activity was revealed in the collaboration of plastic dish-nonadherent and -adherent PEC as the primary and final effectors, respectively. (iii) The appearance of primary effector cells for such an activity was also accelerated in spleen and lymph node cells. (iv) However, a sufficient number of macrophages were always required as the final effectors in their functional expression. (v) These primary effectors were sensitized T lymphocytes which produced lymphokine(s) such as macrophage-activating factors) and which contributed to this augmented cytostatic activity through the activation of macrophages. Thus, this immune serum factor seems to exert functional expression by accelerating the generation of lymphokine-producing delayed-type T lymphocytes, which is also responsible for cytostatic anti-tumor immunity.

AB - A humoral factor capable of augmenting delayed-type hypersensitivity antigen specificity (DAF) is present in the serum of mice sensitized with heterologous erythrocytes to induce a delayed footpad reaction (DFR). In the present study, a similar factor was identified when xenogeneic tumor cells were used as antigens. This factor also could augment the in vitro anti-tumor cytostatic activity against homologous tumor cells, which correlated with in vivo DFR to the same tumor cells. The cytostatic activity augmented by the transfer of this factor had the following characteristics: (i) The activity appeared in the whole peritoneal exudate cells (PEC) from serum recipients at 4 days after the antigenic challenge. (ii) Such an activity was revealed in the collaboration of plastic dish-nonadherent and -adherent PEC as the primary and final effectors, respectively. (iii) The appearance of primary effector cells for such an activity was also accelerated in spleen and lymph node cells. (iv) However, a sufficient number of macrophages were always required as the final effectors in their functional expression. (v) These primary effectors were sensitized T lymphocytes which produced lymphokine(s) such as macrophage-activating factors) and which contributed to this augmented cytostatic activity through the activation of macrophages. Thus, this immune serum factor seems to exert functional expression by accelerating the generation of lymphokine-producing delayed-type T lymphocytes, which is also responsible for cytostatic anti-tumor immunity.

UR - http://www.scopus.com/inward/record.url?scp=0022861354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022861354&partnerID=8YFLogxK

U2 - 10.1016/0008-8749(86)90092-4

DO - 10.1016/0008-8749(86)90092-4

M3 - Article

VL - 103

SP - 311

EP - 325

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 2

ER -